Adolescents and young adults who were recently diagnosed with blood-related cancers have better long-term survival rates than those who were diagnosed in the 1980s, find a new analysis.
Published in the November 1, 2009 issue of Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that significant advances have been made in the treatment of 15 to 24 year-olds with leukemias and lymphomas; however, survival rates in this age group are still lower than those seen in younger children.
Few studies have looked at trends in the long-term survival of adolescents and young adults with blood-related cancers, which include Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute lymphoblastic leukemia, acute myeloblastic leukemia, and chronic myelocytic leukemia.
When the investigators compared SEER data from 1981-1985 with data from 2001-2005, they found that survival significantly improved in each of the five blood-related malignancies. The 10-year survival rates increased from 80.4 percent to 93.4 percent among adolescents and young adults with Hodgkin's lymphoma; from 55.6 percent to 76.2 percent for non-Hodgkin's lymphoma; from 30.5 percent to 52.1 percent for acute lymphoblastic leukemia; from 15.2 percent to 45.1 percent for acute myeloblastic leukemia; and from 0 percent to 74.5 percent for chronic myelocytic leukemia.
When they analyzed the data further, the researchers found that survival improved steadily over the two decades for the lymphomas and chronic myelocytic leukemia, but survival was stable during the late 1990s and early 21st century for the acute leukemias. Also, with the exception of Hodgkin's lymphoma, survival in adolescents and young adults still lags behind survival in children and, in the case of acute myeloblastic leukemia, even behind survival in older adults.
According to the authors, the persistent lower survival rates for adolescents and young adults with acute leukemias compared with children with these diseases remain a major challenge. "More research into how to treat these diseases and how to make sure that all patients have access to the best treatment is needed," said Pulte.